公司資料
Quoin 股價、新聞與催化劑
- 股票代碼:
- QNRX
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.19 USD (+1.96%)
收盤價
最後更新: 2026年8月17日
9.16M USD
市值
股價為何變動
Following the latest company update, “Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results”, QNRX closed down 15.9% at $5.09 on Aug 14, 2026. The move occurred in the trading session associated with this earnings update.
公司概覽
Rare Dermatology Company
Quoin Pharmaceuticals is a clinical-stage specialty pharmaceutical company developing treatments for rare and orphan dermatologic diseases. Its strategy focuses on conditions with limited or no approved therapeutic options and uses topical formulations intended for chronic administration.
QRX003 in Netherton Syndrome
QRX003, also referred to as QYLEKI, is the company's lead topical program for Netherton syndrome. It has received orphan-drug designation in the United States, European Union, and Japan, as well as FDA Fast Track and Rare Pediatric Disease designations.
Peeling Skin Syndrome Expansion
Quoin is expanding QRX003 into peeling skin syndrome, another rare inherited skin disorder. The FDA has cleared the investigational new drug application for this indication, allowing the company to advance a company-sponsored study in the United States and Europe.
QRX009 Rapamycin Platform
QRX009 is a topical rapamycin formulation platform being explored in rare dermatologic conditions including pachyonychia congenita, Gorlin syndrome, and tuberous sclerosis complex. Quoin plans to use investigator-sponsored work and additional regulatory filings to broaden the platform's clinical reach.
未來催化劑
- Initiation of a Phase 2/3 study of QRX003 in peeling skin syndrome in the second half of 2026.
- Submission of an additional IND for the QRX009 platform by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。